ProShare Advisors’s Akcea Therapeutics Inc AKCA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-18,386
| Closed | -$334K | – | 2113 |
|
|
2020
Q3 | $334K | Sell |
18,386
-71
| -0.4% | -$1.01K | ﹤0.01% | 1114 |
|
|
2020
Q2 | $253K | Buy |
18,457
+4,781
| +35% | +$73.8K | ﹤0.01% | 1329 |
|
|
2020
Q1 | $196K | Sell |
13,676
-8,336
| -38% | -$137K | ﹤0.01% | 1015 |
|
|
2019
Q4 | $373K | Sell |
22,012
-4,588
| -17% | -$85.4K | ﹤0.01% | 1222 |
|
|
2019
Q3 | $409K | Sell |
26,600
-1,907
| -7% | -$40.6K | ﹤0.01% | 1060 |
|
|
2019
Q2 | $668K | Sell |
28,507
-3,261
| -10% | -$80.6K | ﹤0.01% | 908 |
|
|
2019
Q1 | $900K | Buy |
31,768
+165
| +0.5% | +$4.81K | 0.01% | 809 |
|
|
2018
Q4 | $953K | Sell |
31,603
-4,914
| -13% | -$138K | 0.01% | 719 |
|
|
2018
Q3 | $1.28M | Sell |
36,517
-1,134
| -3% | -$34.3K | 0.01% | 719 |
|
|
2018
Q2 | $893K | Buy |
37,651
+4,926
| +15% | +$118K | 0.01% | 875 |
|
|
2018
Q1 | $838K | Sell |
32,725
-5,351
| -14% | -$115K | 0.01% | 898 |
|
|
2017
Q4 | $661K | Buy |
+38,076
| New | +$747K | ﹤0.01% | 1000 |
|
ProShare Advisors's AKCA Position: Q4 2020 in Review
ProShare Advisors sold out of Akcea Therapeutics Inc (AKCA) in Q4 2020, closing a stake of 18,386 shares — an estimated $334K sold.
ProShare Advisors first reported a position in AKCA in Q4 2017 and held it in 12 quarters. The position peaked at $1.28M in Q3 2018. 0 funds tracked by Wall St. Rank hold AKCA as of Q4 2020.
- ProShare Advisors reported no remaining Akcea Therapeutics Inc position as of Q4 2020 after selling out during the quarter.
- ProShare Advisors sold 18,386 Akcea Therapeutics Inc shares in Q4 2020, an estimated $334K.
- ProShare Advisors first reported a position in Akcea Therapeutics Inc in Q4 2017 and held it in 12 quarters.
- ProShare Advisors's Akcea Therapeutics Inc position peaked at $1.28M in Q3 2018.
- 0 funds tracked by Wall St. Rank held Akcea Therapeutics Inc as of Q4 2020.
Based on ProShare Advisors's 13F filing for Q4 2020, filed 9 Feb 2021.